1. Home
  2. GRI vs UGRO Comparison

GRI vs UGRO Comparison

Compare GRI & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.47

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Logo urban-gro Inc.

UGRO

urban-gro Inc.

HOLD

Current Price

$2.40

Market Cap

1.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
UGRO
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.8M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
GRI
UGRO
Price
$2.47
$2.40
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$160.00
N/A
AVG Volume (30 Days)
46.8K
76.1K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$40,008,850.00
Revenue This Year
N/A
$98.41
Revenue Next Year
N/A
$23.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.11
52 Week High
$11.12
$4.50

Technical Indicators

Market Signals
Indicator
GRI
UGRO
Relative Strength Index (RSI) 53.75 50.17
Support Level $2.18 $2.12
Resistance Level $2.66 $4.50
Average True Range (ATR) 0.20 0.29
MACD -0.03 -0.10
Stochastic Oscillator 47.89 8.26

Price Performance

Historical Comparison
GRI
UGRO

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About UGRO urban-gro Inc.

Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).

Share on Social Networks: